BRD4 and breast carcinoma: In breast cancer, BRD4 inhibitor combined with radiotherapy reduced PD-L1 and HIF-1α expression, remodeled myeloid cells toward an immunostimulatory phenotype, and expanded CD4+/CD8+ T cell populations (174).